Cipla Ltd

Cipla Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1336, down 0.6% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.25% on the day, quoting at 22478.35. The Sensex is at 72078.38, up 0.23%.Cipla Ltd has eased around 4.23% in last one month.Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has eased around 2.14% in last one month and is currently quoting at 26311.55, down 0.79% on the day. The volume in the stock stood at 6.16 lakh shares today, compared to the daily average of 10.08 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 1335.2, down 1.24% on the day. Cipla Ltd tumbled 11.7% in last one year as compared to a 10.37% slide in NIFTY and a 19.85% spurt in the Nifty Pharma index.The PE of the stock is 33.18 based on TTM earnings ending June 26.

Cipla Ltd. will hold a board meeting on Tuesday, October 27, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, the company said in a filing. The trading window for the company’s securities will be closed from October 1, 2026, to October 29, 2026, for the purpose of financial results, according to the company’s code of conduct.

Cipla Ltd. announced that its Operations and Administrative Committee has allotted 12,168 fully paid-up equity shares of INR 2 each under the Employee Stock Option Scheme 2013 -A and the Cipla Employee Stock Appreciation Rights Scheme 2021, increasing the company’s issued, subscribed and paid-up share capital to INR 1,61,57,41,230 comprising of 80,78,70,615 equity shares.

Cipla Ltd. announced that Venkata Sai Mungara, currently Global Head Supply Chain, will transition to the role of Chief of Manufacturing and Supply Chain Operations of Cipla USA Inc., a wholly owned subsidiary of the company, effective October 1, 2026, and will consequently cease to be a Senior Management Personnel of Cipla Ltd.

Cipla Ltd. announced that Aspergen Limited, a 60:40 joint venture with Kemwell Biopharma Private Limited, has acquired 100% stake in Aspergen Inc., USA, from Cipla (EU) Limited and Kemwell Biopharma UK Limited, making Aspergen Inc., USA a wholly owned subsidiary of Aspergen Limited, India; the restructuring was undertaken to rationalize and simplify the group structure and results in no change to Cipla’s economic interest in Aspergen Inc., USA.

Cipla Ltd. announced that its Operations and Administrative Committee has allotted 5,281 fully paid-up equity shares of INR 2 each under the Employee Stock Option Scheme 2013 -A and the Cipla Employee Stock Appreciation Rights Scheme 2021, increasing the company’s issued, subscribed and paid-up share capital to INR 1,61,57,16,894 comprising of 80,78,58,447 equity shares.

A court order has paved the way for the amalgamation of a wholly-owned subsidiary into its parent company, streamlining the merger process under Company Application No. 114/2026. The scheme, involving the Transferor Company merging into the Transferee Company, does not necessitate the issuance of new shares or negatively impact creditors, leading the court to dispense with shareholder and creditor meetings of the Transferee Company, citing precedents like *Mahaamba Investments Limited*. While meetings are waived, the Transferee Company must still provide notice to shareholders, creditors, and regulatory bodies via various channels, allowing a 30-day period for objections. The Applicant Companies are also required to file details regarding corporate guarantees, pending legal cases, and letters of credit, and post the scheme on their website, followed by an affidavit of service within 10 working days.

Cipla Ltd. announced that its Operations and Administrative Committee has allotted 7,850 fully paid-up equity shares of Rs 2 each under the Employee Stock Option Scheme 2013 -A and the Cipla Employee Stock Appreciation Rights Scheme 2021, increasing the company's issued, subscribed and paid-up share capital to Rs 1,61,57,06,332 comprising of 80,78,53,166 equity shares of face value Rs 2 each.

The board of Cipla at its meeting held on 23 July 2026 has approved the following: Transition of Ashish Adukia, Global Chief Financial Officer, to internal business leadership role. Consequent to such transition, Ashish Adukia has relinquished the position as the Global Chief Financial Officer and Key Managerial Personnel (KMP) of the Company with effect from close of business hours of 23 July 2026. Appointment of Dinesh Jain, Chief ' Corporate Finance, as Global Chief Financial Officer and KMP with effect from 24 July 2026.

Cipla has granted 24,709 stock options and employee stock appreciation rights on 23 July 2026.